Metallo-Liposomes of Ruthenium Used as Promising Vectors of Genetic Material

Gene therapy is a therapeutic process consisting of the transport of genetic material into cells. The design and preparation of novel carriers to transport DNA is an important research line in the medical field. Hybrid compounds such as metallo-liposomes, containing a mixture of lipids, were prepare...

Descripción completa

Detalles Bibliográficos
Autores: Lebrón Romero, José Antonio, Ostos Marcos, Francisco José, López López, Manuel, Moyá Morán, María Luisa, Sales, Carlos, García, Encarnación, García Calderón, Clara Beatriz, García Calderón, Margarita, Peña Gómez, Mª José, Valle Rosado, Iván, Romero Balestra, Fernando, Huertas Sánchez, Pablo, López-Cornejo, María del Pilar
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/97650
Acceso en línea:https://hdl.handle.net/11441/97650
https://doi.org/10.3390/pharmaceutics12050482
Access Level:acceso abierto
Palabra clave:Gene therapy
Metallo-liposomes
Non-toxic nanocarriers
Ruthenium(II)-based lipids
Specificity by cancer cells
Transfection process
id ES_e10ddb523bf0a0bcfd89598dd2d84da3
oai_identifier_str oai:idus.us.es:11441/97650
network_acronym_str ES
network_name_str España
repository_id_str
spelling Metallo-Liposomes of Ruthenium Used as Promising Vectors of Genetic MaterialLebrón Romero, José AntonioOstos Marcos, Francisco JoséLópez López, ManuelMoyá Morán, María LuisaSales, CarlosGarcía, EncarnaciónGarcía Calderón, Clara BeatrizGarcía Calderón, MargaritaPeña Gómez, Mª JoséValle Rosado, IvánRomero Balestra, FernandoHuertas Sánchez, PabloLópez-Cornejo, María del PilarGene therapyMetallo-liposomesNon-toxic nanocarriersRuthenium(II)-based lipidsSpecificity by cancer cellsTransfection processGene therapy is a therapeutic process consisting of the transport of genetic material into cells. The design and preparation of novel carriers to transport DNA is an important research line in the medical field. Hybrid compounds such as metallo-liposomes, containing a mixture of lipids, were prepared and characterized. Cationic metal lipids derived from the [Ru(bpy)3]2+ complex, RuC11C11 or RuC19C19, both with different hydrophobic/lipophilic ratios, were mixed with the phospholipid DOPE. A relation between the size and the molar fraction α was found and a multidisciplinary study about the interaction between the metallo-liposomes and DNA was performed. The metallo-liposomes/DNA association was quantified and a relationship between Kapp and α was obtained. Techniques such as AFM, SEM, zeta potential, dynamic light scattering and agarose gel electrophoresis demonstrated the formation of lipoplexes and showed the structure of the liposomes. L/D values corresponding to the polynucleotide's condensation were estimated. In vitro assays proved the low cell toxicity of the metallo-liposomes, lower for normal cells than for cancer cell lines, and a good internalization into cells. The latter as well as the transfection measurements carried out with plasmid DNA pEGFP-C1 have demonstrated a good availability of the Ru(II)-based liposomes for being used as non-toxic nanovectors in gene therapy.España Consejería de Educación y Ciencia de la Junta de Andalucía (Proyecto de Excelencia P12-FQM-1105, FQM-206 and FQM-274, and PI-0005-2018)España,, Universidad de Sevilla, VI Plan Propio Universidad de Sevilla (PP2018-10338)España Ministerio de Ciencia, Innovación y Universidades (RTI2018-100692-B-I00)MDPIQuímica Física2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/97650https://doi.org/10.3390/pharmaceutics12050482reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésPharmaceutics, 12 (5), 482.(Proyecto de Excelencia P12-FQM-1105, FQM-206 and FQM-274, and PI-0005-2018)PP2018-10338RTI2018-100692-B-I00http://dx.doi.org/10.3390/pharmaceutics12050482info:eu-repo/semantics/openAccessoai:idus.us.es:11441/976502026-06-17T12:51:07Z
dc.title.none.fl_str_mv Metallo-Liposomes of Ruthenium Used as Promising Vectors of Genetic Material
title Metallo-Liposomes of Ruthenium Used as Promising Vectors of Genetic Material
spellingShingle Metallo-Liposomes of Ruthenium Used as Promising Vectors of Genetic Material
Lebrón Romero, José Antonio
Gene therapy
Metallo-liposomes
Non-toxic nanocarriers
Ruthenium(II)-based lipids
Specificity by cancer cells
Transfection process
title_short Metallo-Liposomes of Ruthenium Used as Promising Vectors of Genetic Material
title_full Metallo-Liposomes of Ruthenium Used as Promising Vectors of Genetic Material
title_fullStr Metallo-Liposomes of Ruthenium Used as Promising Vectors of Genetic Material
title_full_unstemmed Metallo-Liposomes of Ruthenium Used as Promising Vectors of Genetic Material
title_sort Metallo-Liposomes of Ruthenium Used as Promising Vectors of Genetic Material
dc.creator.none.fl_str_mv Lebrón Romero, José Antonio
Ostos Marcos, Francisco José
López López, Manuel
Moyá Morán, María Luisa
Sales, Carlos
García, Encarnación
García Calderón, Clara Beatriz
García Calderón, Margarita
Peña Gómez, Mª José
Valle Rosado, Iván
Romero Balestra, Fernando
Huertas Sánchez, Pablo
López-Cornejo, María del Pilar
author Lebrón Romero, José Antonio
author_facet Lebrón Romero, José Antonio
Ostos Marcos, Francisco José
López López, Manuel
Moyá Morán, María Luisa
Sales, Carlos
García, Encarnación
García Calderón, Clara Beatriz
García Calderón, Margarita
Peña Gómez, Mª José
Valle Rosado, Iván
Romero Balestra, Fernando
Huertas Sánchez, Pablo
López-Cornejo, María del Pilar
author_role author
author2 Ostos Marcos, Francisco José
López López, Manuel
Moyá Morán, María Luisa
Sales, Carlos
García, Encarnación
García Calderón, Clara Beatriz
García Calderón, Margarita
Peña Gómez, Mª José
Valle Rosado, Iván
Romero Balestra, Fernando
Huertas Sánchez, Pablo
López-Cornejo, María del Pilar
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Química Física
dc.subject.none.fl_str_mv Gene therapy
Metallo-liposomes
Non-toxic nanocarriers
Ruthenium(II)-based lipids
Specificity by cancer cells
Transfection process
topic Gene therapy
Metallo-liposomes
Non-toxic nanocarriers
Ruthenium(II)-based lipids
Specificity by cancer cells
Transfection process
description Gene therapy is a therapeutic process consisting of the transport of genetic material into cells. The design and preparation of novel carriers to transport DNA is an important research line in the medical field. Hybrid compounds such as metallo-liposomes, containing a mixture of lipids, were prepared and characterized. Cationic metal lipids derived from the [Ru(bpy)3]2+ complex, RuC11C11 or RuC19C19, both with different hydrophobic/lipophilic ratios, were mixed with the phospholipid DOPE. A relation between the size and the molar fraction α was found and a multidisciplinary study about the interaction between the metallo-liposomes and DNA was performed. The metallo-liposomes/DNA association was quantified and a relationship between Kapp and α was obtained. Techniques such as AFM, SEM, zeta potential, dynamic light scattering and agarose gel electrophoresis demonstrated the formation of lipoplexes and showed the structure of the liposomes. L/D values corresponding to the polynucleotide's condensation were estimated. In vitro assays proved the low cell toxicity of the metallo-liposomes, lower for normal cells than for cancer cell lines, and a good internalization into cells. The latter as well as the transfection measurements carried out with plasmid DNA pEGFP-C1 have demonstrated a good availability of the Ru(II)-based liposomes for being used as non-toxic nanovectors in gene therapy.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/97650
https://doi.org/10.3390/pharmaceutics12050482
url https://hdl.handle.net/11441/97650
https://doi.org/10.3390/pharmaceutics12050482
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Pharmaceutics, 12 (5), 482.
(Proyecto de Excelencia P12-FQM-1105, FQM-206 and FQM-274, and PI-0005-2018)
PP2018-10338
RTI2018-100692-B-I00
http://dx.doi.org/10.3390/pharmaceutics12050482
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422257860771840
score 15,300724